3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
16
Phase 1
8
Phase 3
4
Phase 1/2
4
Phase 2/3
2
Phase 4
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Breast Neoplasms
11
Stomach Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
HER2-positive Breast Cancer
1
HER-2 Positive Gastric Cancer
1
Cardiotoxicity
1
Brain Neoplasms
1
Interventions
Dexamethasone
8
Oxycodone
6
Epoetin Alfa
5
Propofol
4
Palonosetron
4
Meropenem
4
Zoledronic Acid
3
Vancomycin
3
Sevoflurane
3
Ondansetron
3
Naloxone
3
Everolimus
3
Ciprofloxacin
3
Cholecalciferol
3
Ceftazidime
3
Cefepime
3
Calcium Dobesilate
3
Bevacizumab
3
Aspirin
3
Aprepitant
3
peginterferon alfa-2a
2
edoxaban
2
apixaban
2
apatinib
2
Vitamin B 12
2
Vincristine
2
Tobacco Use Cessation Devices
2
Teicoplanin
2
Tablets
2
Surgical Procedures, Operative
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Neoplasms
×
Trastuzumab
×
Clear all
NCT06031233
2026-03-30
MINUTE
Isala
Phase 4
Recruiting
776 enrolled